

**Validation by Immunohistochemistry:** IHC staining for MAGP2 was performed on tissue array slides containing a unique set of 81 high-grade, advanced stage serous ovarian cancer tissues, for use as a validation set. Staining was performed using a commercially available anti-MAGP2 (rabbit) primary antibody (Rockland Inc., Gilbertsville, MD), along with EnVision Labeled Polymer-AP mouse/rabbit secondary antibody, and developed using Fast Red Substrate System (DakoCytomation, Carpinteria, CA). Staining intensities were quantified by the Image-Pro Plus 5.1 software (Media Cybernetics, Silver Springs, MD), using the average background corrected intensities, averaged over all replicates. Scoring was performed by reviewers blinded to any clinical data associated with the investigation.

**Correlation between MAGP2 protein expression levels and overall survival:** In the validation set, MAGP2 protein expression levels were compared to overall survival by Cox regression analysis. The results showed that protein expression, adjusted for debulking status, showed a significant correlation with poor survival (HR=1.02, 95% CI: 1.01, 1.03, p=0.001). Age was not a significant variable in this data set.